{"url_path":"/sec/rnaz/8-k/2026-07-20/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/1829635/0001104659-26-085073-index.html","accession_number":"0001104659-26-085073","cik":"0001829635","ticker":"RNAZ","issuer_name":"Transcode Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1829635/0001104659-26-085073-index.html","primary_entity_key":"0001829635","primary_entity_name":"Transcode Therapeutics, Inc."},"word_count":869,"has_tables":true,"body_markdown":"**Item 5.07**\n**Submission of Matters to a Vote of Security Holders.**\n\n \n\nOn July 202, 2026, TransCode Therapeutics, Inc. (the “Company”)\nheld its 2026 Annual Meeting of Stockholder (the “Annual Meeting”). Present at the Annual Meeting in person or by proxy were\nholders of 495,162 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), representing\n52.1% of the voting power of the shares of Common Stock as of the close of business on May 28, 2026, the record date for the Annual Meeting,\nand constituting a quorum for the transaction of business. All matters voted upon at the Annual Meeting were approved with the required\nvotes, including for purposes of applicable Nasdaq Listing Rules. The matters that were voted upon at the Annual Meeting, and the number\nof votes cast for or against, as well as the number of abstentions and broker non-votes, as to each such matter are set forth below.\n\n \n\n**(i)****Approval, for the purposes of complying with the applicable provisions of Nasdaq Listing Rule 5635, of the issuance of the\nCompany’s Common Stock upon conversion of the Company’s Series A Non-Voting Convertible Preferred Stock, par value $0.0001\nper share (“Series A Preferred Stock”), and the Company’s Series B Non-Voting Convertible Preferred Stock, par\nvalue $0.0001 per share (“Series B Preferred Stock”) (“Proposal 1”).**\n\n \n\nThe conversion of the Series A Preferred Stock and Series B Preferred\nStock into shares of Common Stock and the issuance of the Common Stock thereunder was approved. The following votes were tabulated:\n\n \n\nFor \nAgainst \nAbstain \nBroker Non-Votes\n\n143,162 \n11,518 \n742 \n 256,450\n\n \n\n**(ii)****Approval, for the purposes of complying with the applicable provisions of Nasdaq Listing Rule 5635(a), of the issuance of\nthe Company’s Common Stock upon conversion of our Series C Non-Voting Convertible Preferred Stock, par value $0.0001 per share\n(“Series C Preferred Stock”) (“Proposal 2”).**\n\n \n\nThe conversion of the Series C Preferred Stock into shares of Common\nStock and the issuance of the Common Stock thereunder was approved. The following votes were tabulated:\n\n \n\nFor \nAgainst \nAbstain \nBroker Non-Votes\n\n140,517 \n14,216 \n689 \n 256,450\n\n \n\n(iii)Approval, for the purposes of complying with the applicable provisions of Nasdaq Listing Rule 5635(d), of the issuance of shares\nof the Company’s Common Stock pursuant to the Standby Equity Purchase Agreement, dated as of April 6, 2026, by and between the Company\nand YA II PN, Ltd. (the “SEPA”) and convertible promissory notes issued or to be issued to by the Company to YA II PN, Ltd.\n(the “Convertible Notes”).\n\n \n\nThe issuance of Common Stock pursuant to the SEPA and Convertible Notes\nwas approved. The following votes were tabulated:\n\n \n\nFor \nAgainst \nAbstain \nBroker Non-Votes\n\n108,292 \n14,170 \n32,960 \n 256,450\n\n \n\n2\n\n \n\n \n\n(iv)Election of six (6) directors, Philippe P. Calais, PharmD, PhD, Elizabeth Czerepak, Thomas A. Fitzgerald, Erik Manting, PhD, Magda\nMarquet, PhD and Jack E. Stover for one-year terms until his or her successor has been duly elected and qualified, or until his or her\nearlier death, resignation or removal.\n\n \n\nThe Company’s stockholders voted to approve the election of each\nof the director nominees. The following votes were tabulated:\n\n \n\nDirector Nominee\n \nFor\n \n \nWithhold\n \n \nBroker Non-Votes\n \n\nPhilippe P. Calais\n \n \n149,389\n \n \n \n6,033\n \n \n \n256,450\n \n\nElizabeth Czerepak\n \n \n149,336\n \n \n \n6,086\n \n \n \n256,450\n \n\nThomas A. Fitzgerald\n \n \n149,321\n \n \n \n6,101\n \n \n \n256,450\n \n\nErik Manting\n \n \n149,628\n \n \n \n5,794\n \n \n \n256,450\n \n\nMagda Marquet\n \n \n149,584\n \n \n \n5,838\n \n \n \n256,450\n \n\nJack E. Stover\n \n \n149,416\n \n \n \n6,006\n \n \n \n256,450\n \n\n \n\n**(v)****Approval of an amendment to the TransCode Therapeutics, Inc. 2021 Stock Option and Incentive Plan to increase the number of shares\navailable for issuance thereunder by 1,734,262 shares.**\n\n \n\nThe Company’s stockholders approved the amendment to the TransCode\nTherapeutics, Inc. 2021 Stock Option and Incentive Plan. The following votes were tabulated:\n\n \n\nFor \nAgainst \nAbstain \nBroker Non-Votes\n\n124,643 \n30,449 \n330 \n 256,450\n\n \n\n**(vi)****Ratification of the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for\nthe fiscal year ending December 31, 2026.**\n\n \n\nThe Company’s stockholders ratified the appointment\nof WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the fiscal year ending December 31,\n2026. The following votes were tabulated:\n\n \n\nFor \nAgainst \nAbstain\n\n393,497 \n18,172 \n 203\n\n \n\n**(vii)****Approval of the adjournment of the Annual Meeting to a later date or dates, if necessary or appropriate.**\n\n \n\nThe Company’s stockholders approved the adjournment\nof the Annual Meeting, if necessary. No corresponding motion was made to approve an adjournment to the Annual Meeting following approval\nof the proposal, because sufficient votes were received to approve all other matters brought before the Annual Meeting. The following\nvotes were tabulated:\n\n \n\nFor \nAgainst \nAbstain \nBroker Non-Votes\n\n137,062 \n18,253 \n107 \n 256,450\n\n \n\nThe proposals are described in detail in the Company’s\nDefinitive Proxy Statement filed with the Securities and Exchange Commission on June 2, 2026, as supplemented by the supplement to the\nDefinitive Proxy Statement filed with the Securities and Exchange Commission on July 17, 2026.\n\n \n\nNasdaq has approved the Company’s Nasdaq Initial Listing Application\nrequired under Nasdaq Listing Rules 5110 and 5635(b) in connection with the approval of Proposal 1 and Proposal 2.\n\n \n\n3\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nthe Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**TRANSCODE\nTHERAPEUTICS, INC.**\n\n \n \n \n\n \nBy:\n/s/\nThomas A. Fitzgerald\n\n \nName:\nThomas A. Fitzgerald\n\n \nTitle:\nChief\nFinancial Officer and Secretary\n\nJuly\n20, 2026\n \n \n\n \n\n4"}